cytidine monophosphate has been researched along with Myelodysplastic Syndromes in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 12 (85.71) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hatta, Y; Hirabayashi, Y; Horikoshi, A; Iriyama, N; Kobayashi, S; Kodaira, H; Matsukawa, Y; Miura, K; Takahashi, H; Takeuchi, J; Uchino, Y | 1 |
| Arimori, K; Fujiwara, H; Fukuda, R; Kawada, H; Masumoto, A; Ogawa, Y; Ohbayashi, Y; Sasao, T; Umeda, Y; Watanabe, S | 1 |
| Arie, Y; Hirai, M; Kikukawa, M; Kodo, H; Kumakawa, T; Mizutani, R; Mori, M; Murai, Y; Nakamura, N; Tsutsumi, H | 1 |
| Mori, N; Murakami, S; Nagata, K; Nakanishi, M; Nakata, K; Ogawa, R; Serino, Y; Takazawa, A; Tonai, S; Wake, A | 1 |
| Arai, T; Araki, M; Hayakawa, K; Narimiya, S; Shibuya, C; Takaya, T; Toshima, S; Uchida, A; Yasuda, Y; Yoshimi, N | 1 |
| Andoh, K; Fujimoto, H; Funasako, M; Hata, N; Itoh, K; Itoh, Y; Nakai, S; Nishi, T; Ohata, M; Ono, H; Sato, H; Sato, Y; Taniji, M; Ueda, A | 1 |
| Chuhjo, T; Katoh, T; Kaya, H; Matano, S; Matsuda, T; Murashima, M; Nakamura, S; Ohtake, S; Okumura, H; Takamatsu, H; Takeshima, M; Watanabe, A; Yamauchi, H; Yoshida, T | 1 |
| Ito, T; Konishi, H; Maesako, Y; Mori, S; Ueda, Y; Yagiri, Y | 1 |
| Hirano, M; Imai, K; Kosaka, M; Mizoguchi, H; Nakamura, T; Ohno, R; Takatsuki, K; Tatsumi, N; Toyama, K; Yamaya, T | 1 |
| Furukawa, Y; Hiyoshi, M; Im, T; Inoue, K; Kishida, T; Nakao, Y; Ohira, H; Ota, K; Yamane, T; Yasui, Y | 1 |
| Fukuoka, M; Hattori, M; Hirota, Y; Miyazaki, T; Nakamura, T; Niitani, H; Ohta, K; Suzuoki, Y; Tanaka, M; Yoshida, Y | 1 |
| Kimura, I; Kimura, K; Masaoka, T; Nakamura, T; Ohno, R; Ohshima, T; Tatsumi, N; Yamada, K | 1 |
| Imamura, S; Kamiya, K; Kawai, Y; Nakamura, T; Tsutani, H; Ueda, T; Wano, Y | 1 |
| Kamiya, K; Nakamura, T; Sugiyama, M; Tanaka, T; Tsutani, H; Ueda, T; Wano, Y | 1 |
5 trial(s) available for cytidine monophosphate and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Treatment of acute myeloid leukemia and myelodysplastic syndrome with orally administered cytarabine ocfosfate and granulocyte colony-stimulating factor.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 1997 |
[A pharmacokinetic study of the value of oral cytarabine ocfosfate in the treatment of hematological malignancies].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Time Factors | 1998 |
Treatment of myelodysplastic syndromes with orally administered 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate.
Topics: Adult; Aged; Aged, 80 and over; Arabinonucleotides; Cytidine Monophosphate; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 1991 |
[Phase I study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate)].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Diarrhea; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Middle Aged; Myelodysplastic Syndromes; Nausea; Vomiting | 1990 |
[Phase II study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate) on hematological malignancies].
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Drug Administration Schedule; Drug Evaluation; Female; Humans; Japan; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Nausea; Remission Induction; Vomiting | 1990 |
9 other study(ies) available for cytidine monophosphate and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Efficacy of oral cytarabine ocfosfate and etoposide in the treatment of elderly patients with higher-risk myelodysplastic syndromes compared to that in elderly acute myeloid leukemia patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytidine Monophosphate; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Treatment Outcome | 2013 |
[Effects of cytarabine ocfosfate on colony-stimulating factor in myelodysplastic syndrome with monosomy 7].
Topics: Adult; Arabinonucleotides; Chromosomes, Human, Pair 7; Cytidine Monophosphate; Drug Resistance; Granulocyte Colony-Stimulating Factor; Humans; Karyotyping; Leukocyte Count; Male; Monosomy; Myelodysplastic Syndromes | 1994 |
[Plasma concentration of cytosine arabinoside (Ara-C) in the elderly patients with hematological malignancy treated by Ara-C or cytarabine ocfosfate (SPAC)].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes | 1995 |
[Successful treatment of acute myelomonocytic leukemia developed from MDS with cytarabine ocfosfate (SPAC)].
Topics: Aged; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Drug Administration Schedule; Female; Humans; Leukemia, Myelomonocytic, Acute; Myelodysplastic Syndromes; Remission Induction | 1995 |
[Successful treatment of myelodysplastic syndrome with cytarabine ocfosfate].
Topics: Aged; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Humans; Male; Myelodysplastic Syndromes; Remission Induction | 1994 |
[Five cases of myelodysplastic syndrome treated with cytarabine ocfosfate].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytidine Monophosphate; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1996 |
[Clinical effects of stearyl-ara-CMP (YNK-01) on chronic hematologic malignancies].
Topics: Adult; Aged; Antineoplastic Agents; Arabinonucleotides; Chronic Disease; Cytidine Monophosphate; Drug Evaluation; Female; Humans; Leukemia; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Remission Induction | 1991 |
Successful treatment of myelodysplastic syndrome with 1-beta-D-arabinofuranosylcytosine 5'-stearylphosphate.
Topics: Aged; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1990 |
[Pharmacokinetics of stearyl-ara-CMP (YNK-01) in patients with hematologic neoplasms].
Topics: Acute Disease; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Cytosine Nucleotides; Drug Evaluation; Humans; Leukemia; Myelodysplastic Syndromes | 1989 |